Personnel‎ > ‎

Lab Members

 
Marta Edwards, MD, joined the Castro/Lowenstein Lab in January 2013. She received M.D. degree from the Medical Academy of Lublin, Poland.  After moving to Michigan she worked in Immunohistochemistry, the Department of Pathology.  Later she moved to research and worked in several laboratories:

- Kresge Hearing Institute, Department Of Otolaryngology with R. Altschuler, Ph.D.
-Served as a Technical Director of the Morphology Core, Center For Organogenesis in the Department of Cell and Developmental
  Biology under Deborah Gumucio, Ph.D.
-Department of Pediatrics and Pulmonary Medicine with Marc Hershenson, M.D.
-Department of Internal Medicine and Genetics with Steven Weiss, M.D.

Marta is now the lab’s manager and her responsibilities include all aspects of histology, immunohistochemistry, microscopy, including training other lab members in these procedures. She is also responsible for sample preparation, and imaging on Sigma 3View Scanning Electron Microscope and sectioning on a Leica Cryomacrotome.  Additionally, Marta ensures that the lab and its members have the necessary supplies and materials to keep our busy lab functioning in top condition.
 
Padma Kadiyala, B - graduated from the University of Michigan-Dearborn with a Bachelor’s of Science in Biochemistry in 2014. As an undergraduate, she has been an active part of multiple on campus labs, where she gained strong working experience in the fields of analytically chemistry, biochemistry and biology. Outside of lab she has been a part of honors transfers innovators, chemistry and biochemistry student organizations, where she developed a tutoring program for helping special needs children.

Currently she is working on elucidating how glioma cells escape immune surveillance to fabricate an immune suppressed microenvironment. Her study primarily focuses on gaining an insight into GBM tumor biology mediated by Toll-like receptors (TLRs), which facilitate growth, maturation, and migration of immune cells. She is also working on utilizing nanoparticle as means of delivering chemotherapeutics to the tumor microenvironment past the blood brain barrier. She is interested in advancing her work in the field of life-sciences and designing novel therapeutics to treat GBM effectively. 
 
Flor Mendez, BS, is a graduate of the University of Houston, Cullen College of Engineering with a BS in Biomedical Engineering.  Currently, Ms. Mendez is a student at the University of Michigan and is enrolled in the Program in Biomedical Sciences.  She has earned the prestigious Rackham Merit Fellowship and the Patten Fellow award from CDB. Ms Mendez is working toward a PhD in Biomedical Science.  Ms. Mendez joined the Castro-Lowenstein lab in May 20154 as a rotation student.  She was an immediate fit with our group and Ms. Mendez decided to complete her PIBS training with us.  After passing her preliminary exam with exemplary marks, she is on track to complete her training in 2016.
 
Felipe Núñez Aguilera, PhD, is a Biologist and holds a PhD in Cell and Molecular Biology from University of Concepcion, Chile, where he worked in transcriptional regulation of genes related with gastrointestinal cancer and the Wnt/b-catenin signaling pathway until 2010. He then moved to Buenos Aires, Argentina, to work in the Laboratory of Molecular and Cellular Therapy under the supervision of Dr. Osvaldo Podjahcer at the Leloir Institute Foundation. There, Felipe worked on the development of a novel Oncolytic Adenovirus vector for gene therapy implementation in gastrointestinal and pancreatic cancer. The replication of these novel vectors was restricted to tumor cells by using specific tumor promoters in conjunction with a novel enhancer element that involves aspects of epigenetics regulation to improve their activity.

In September of 2013, Felipe joined the Castro-Lowenstein Laboratory to study the pro- and anti-tumor mechanisms mediated by HMGB1 and another genes involved in DNA repair in mouse models of Glioblastoma multiforme (GBM). To accomplish this, Felipe will attempt the disruption of target genes using the CRISPR system for genome editing and the development of conditional HMGB1 KO mice. Felipe’s goal is to establish the basis for generating new treatments for GBM based at manipulating the HMGB1 mediated signaling cascade, as well as other genes that may mediate DNA repair and genome stability. Ultimately, these novel therapeutic approached could be translated into the clinic in Phase I trials 
for GBM patients.




Comments